Trevena, Inc., a biopharmaceutical company, develops therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. Its product candidates include OLINVO injection, a G protein biased ligand of the µ opioid receptor that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in Phase I clinical study for the treatment of migraine; and TRV734, a small molecule G protein biased ligand of the µ opioid receptor that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure. The company was founded in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TRVN
CUSIPN/A
Phone610-354-8840
Debt
Debt-to-Equity Ratio0.35
Current Ratio4.11
Quick Ratio4.11
Price-To-Earnings
Trailing P/E Ratio-1.35
Forward P/E Ratio-2.36
P/E GrowthN/A
Sales & Book Value
Annual Sales$3.75 million
Price / Sales31.55
Cash FlowN/A
Price / CashN/A
Book Value$0.56 per share
Price / Book2.91
Profitability
EPS (Most Recent Fiscal Year)($1.21)
Net Income$-71,860,000.00
Net MarginsN/A
Return on Equity-138.85%
Return on Assets-75.78%
Miscellaneous
Employees51
Outstanding Shares72,580,000
Trevena (NASDAQ:TRVN) Frequently Asked Questions
What is Trevena's stock symbol?
Trevena trades on the NASDAQ under the ticker symbol "TRVN."
How were Trevena's earnings last quarter?
Trevena Inc (NASDAQ:TRVN) posted its quarterly earnings results on Thursday, May, 3rd. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.05. View Trevena's Earnings History.
When is Trevena's next earnings date?
What price target have analysts set for TRVN?
5 Wall Street analysts have issued 12 month price objectives for Trevena's shares. Their predictions range from $2.50 to $10.00. On average, they anticipate Trevena's share price to reach $6.30 in the next twelve months. View Analyst Ratings for Trevena.
Who are some of Trevena's key competitors?
Some companies that are related to Trevena include Verastem (VSTM), Concert Pharmaceuticals (CNCE), Depomed (DEPO), Unum Therapeutics (UMRX), Cytokinetics (CYTK), ZEALAND PHARMA/S (ZEAL), ArQule (ARQL), Dermira (DERM), Sinovac Biotech (SVA), Mersana Therapeutics (MRSN), Evelo Biosciences (EVLO), GTX (GTXI), Achillion Pharmaceuticals (ACHN), Savara (SVRA) and Albireo Pharma (ALBO).
Who are Trevena's key executives?
Trevena's management team includes the folowing people:
- Dr. Maxine Gowen, CEO, Pres & Exec. Director (Age 60)
- Ms. Carrie L. Bourdow, Exec. VP & COO (Age 55)
- Dr. Howard A. Rockman M.D., Scientific Founder, Consultant and Member of Scientific Advisory Board
- Dr. Jonathan Violin Ph.D., Sr. VP of Scientific Affairs & Investor Relations Officer (Age 43)
- Mr. John M. Limongelli, Chief Admin. Officer, Sr. VP, Gen. Counsel & Corp. Sec. (Age 48)
Has Trevena been receiving favorable news coverage?
Media headlines about TRVN stock have been trending somewhat negative recently, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Trevena earned a coverage optimism score of -0.02 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 46.70 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
Who are Trevena's major shareholders?
Trevena's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Dimensional Fund Advisors LP (1.28%), Northern Trust Corp (0.85%), Millennium Management LLC (0.70%), Schwab Charles Investment Management Inc. (0.22%), GSA Capital Partners LLP (0.18%) and JPMorgan Chase & Co. (0.13%). Company insiders that own Trevena stock include Carrie L Bourdow, Maxine Gowen and Yacoub Habib. View Institutional Ownership Trends for Trevena.
Which institutional investors are selling Trevena stock?
Which institutional investors are buying Trevena stock?
TRVN stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, JPMorgan Chase & Co., Schwab Charles Investment Management Inc. and Northern Trust Corp. Company insiders that have bought Trevena stock in the last two years include Carrie L Bourdow, Maxine Gowen and Yacoub Habib. View Insider Buying and Selling for Trevena.
How do I buy shares of Trevena?
Shares of TRVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Trevena's stock price today?
One share of TRVN stock can currently be purchased for approximately $1.63.
How big of a company is Trevena?
Trevena has a market capitalization of $123.39 million and generates $3.75 million in revenue each year. The biopharmaceutical company earns $-71,860,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis. Trevena employs 51 workers across the globe.
How can I contact Trevena?
Trevena's mailing address is 955 Chesterbrook Boulevard Suite 200, Chesterbrook PA, 19087. The biopharmaceutical company can be reached via phone at 610-354-8840 or via email at [email protected]
MarketBeat Community Rating for Trevena (TRVN)
MarketBeat's community ratings are surveys of what our community members think about Trevena and other stocks. Vote "Outperform" if you believe TRVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
